{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:05:04Z","timestamp":1779865504928,"version":"3.53.1"},"publisher-location":"Berlin, Heidelberg","reference-count":147,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/82_2026_345","type":"book-chapter","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T06:43:53Z","timestamp":1779864233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adoptive T-Cell Immunotherapy"],"prefix":"10.1007","author":[{"given":"Stephen","family":"Gottschalk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona M.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"345_CR1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymthe.2020.09.011","volume":"29","author":"L Amini","year":"2021","unstructured":"Amini L, Wagner DL, Rossler U et al (2021) CRISPR-Cas 9-edited tacrolimus-resistant antiviral T cells for advanced adoptive immunotherapy in transplant recipients. Mol Ther 29:32\u201346","journal-title":"Mol Ther"},{"key":"345_CR2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830021","volume":"13","author":"G Bajwa","year":"2022","unstructured":"Bajwa G, Arber C (2022) Rapid generation of TCR and CD8alphabeta transgenic virus specific T cells for immunotherapy of leukemia. Front Immunol 13:830021","journal-title":"Front Immunol"},{"key":"345_CR3","doi-asserted-by":"crossref","unstructured":"Bauer M, Jasinski-Bergner S, Mandelboim O et al (2021) Epstein-Barr virus-associated malignancies and immune escape: the role of the tumor microenvironment and tumor cell evasion strategies. Cancers (Basel) 13","DOI":"10.3390\/cancers13205189"},{"key":"345_CR4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684642","volume":"12","author":"M Bell","year":"2021","unstructured":"Bell M, Gottschalk S (2021) Engineered cytokine signaling to improve CAR T cell effector function. Front Immunol 12:684642","journal-title":"Front Immunol"},{"key":"345_CR5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41551-023-01143-w","volume":"8","author":"M Bell","year":"2024","unstructured":"Bell M, Lange S, Sejdiu BI et al (2024) Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK\/STAT signalling. Nat Biomed Eng 8:380\u2013396","journal-title":"Nat Biomed Eng"},{"key":"345_CR6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W et al (2019) Defining 'T cell exhaustion'. Nat Rev Immunol 19:665\u2013674","journal-title":"Nat Rev Immunol"},{"key":"345_CR7","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","volume":"99","author":"CM Bollard","year":"2002","unstructured":"Bollard CM, Rossig C, Calonge MJ et al (2002) Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99:3179\u20133187","journal-title":"Blood"},{"key":"345_CR8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","volume":"200","author":"CM Bollard","year":"2004","unstructured":"Bollard CM, Aguilar L, Straathof KC et al (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 200:1623\u20131633","journal-title":"J Exp Med"},{"key":"345_CR9","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","volume":"110","author":"CM Bollard","year":"2007","unstructured":"Bollard CM, Gottschalk S, Leen AM et al (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110:2838\u20132845","journal-title":"Blood"},{"key":"345_CR10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM, Gottschalk S, Torrano V et al (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32:798\u2013808","journal-title":"J Clin Oncol"},{"key":"345_CR11","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","volume":"36","author":"CM Bollard","year":"2018","unstructured":"Bollard CM, Tripic T, Cruz CR et al (2018) Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma. J Clin Oncol 36:1128\u20131139","journal-title":"J Clin Oncol"},{"key":"345_CR12","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1182\/blood-2009-07-228387","volume":"114","author":"J Brewin","year":"2009","unstructured":"Brewin J, Mancao C, Straathof K et al (2009) Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 114:4792\u20134803","journal-title":"Blood"},{"key":"345_CR13","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS (2024a) CAR T cells and T-cell therapies for cancer: a translational science review. JAMA 332:1924\u20131935","journal-title":"JAMA"},{"key":"345_CR14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","volume":"8","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Natrakul DA, Karrs J et al (2024b) Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Adv 8:802\u2013814","journal-title":"Blood Adv"},{"key":"345_CR15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20:359\u2013371","journal-title":"Nat Rev Clin Oncol"},{"key":"345_CR16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nchembio.2565","volume":"14","author":"ZL Chang","year":"2018","unstructured":"Chang ZL, Lorenzini MH, Chen X et al (2018) Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat Chem Biol 14:317\u2013324","journal-title":"Nat Chem Biol"},{"key":"345_CR17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, L\u00f3pez-Moyado IF, Seo H et al (2019) NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567:530\u2013534","journal-title":"Nature"},{"key":"345_CR18","doi-asserted-by":"crossref","unstructured":"Chesney J, Lewis KD, Kluger H et al (2022) Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer 10","DOI":"10.1136\/jitc-2022-005755"},{"key":"345_CR19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","volume":"23","author":"WK Chia","year":"2012","unstructured":"Chia WK, Wang WW, Teo M et al (2012) A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol 23:997\u20131005","journal-title":"Ann Oncol"},{"key":"345_CR20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","volume":"22","author":"WK Chia","year":"2014","unstructured":"Chia WK, Teo M, Wang WW et al (2014) Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22:132\u2013139","journal-title":"Mol Ther"},{"key":"345_CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.1430","volume":"94","author":"D Chua","year":"2001","unstructured":"Chua D, Huang J, Zheng B et al (2001) Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 94:73\u201380","journal-title":"Int J Cancer"},{"key":"345_CR22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006061","volume":"5","author":"M Cobbold","year":"2013","unstructured":"Cobbold M, De La Pena H, Norris A et al (2013) MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med 5:203ra125","journal-title":"Sci Transl Med"},{"key":"345_CR23","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","volume":"99","author":"P Comoli","year":"2002","unstructured":"Comoli P, Labirio M, Basso S et al (2002) Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99:2592\u20132598","journal-title":"Blood"},{"key":"345_CR24","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","volume":"23","author":"P Comoli","year":"2005","unstructured":"Comoli P, Pedrazzoli P, Maccario R et al (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23:8942\u20138949","journal-title":"J Clin Oncol"},{"key":"345_CR25","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/bloodadvances.2023011562","volume":"8","author":"SS Dadwal","year":"2024","unstructured":"Dadwal SS, Bansal R, Schuster MW et al (2024) Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients. Blood Adv 8:4740\u20134750","journal-title":"Blood Adv"},{"key":"345_CR26","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N (2022) Epstein-Barr virus: biology and clinical disease. Cell 185:3652\u20133670","journal-title":"Cell"},{"key":"345_CR27","doi-asserted-by":"crossref","first-page":"1677060","DOI":"10.3389\/fonc.2025.1677060","volume":"15","author":"S Datta","year":"2025","unstructured":"Datta S, Gogia A, Mallick S (2025) Epstein-Barr virus-associated lymphomas: biology, molecular genomics and precision oncology. Front Oncol 15:1677060","journal-title":"Front Oncol"},{"key":"345_CR28","first-page":"4784","volume":"114","author":"AB De","year":"2009","unstructured":"De AB, Dotti G, Quintarelli C et al (2009) Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 114:4784\u20134791","journal-title":"Blood"},{"key":"345_CR29","volume":"6","author":"C DeRenzo","year":"2018","unstructured":"DeRenzo C, Kalra M, Ramos C et al (2018) O17 infusion of TGF\u03b2-resistant EBV-specific T-cells post cytoreductive chemotherapy is safe and associated with clinical benefit in patients with recurrent\/metastatic NPC. J Immunother Cancer 6:114","journal-title":"J Immunother Cancer"},{"key":"345_CR30","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi A, De Angelis B, Rooney CM et al (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113:6392\u20136402","journal-title":"Blood"},{"key":"345_CR31","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673\u20131683","journal-title":"N Engl J Med"},{"key":"345_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","volume":"14","author":"PJ Farrell","year":"2019","unstructured":"Farrell PJ (2019) Epstein-Barr virus and cancer. Annu Rev Pathol 14:29\u201353","journal-title":"Annu Rev Pathol"},{"key":"345_CR33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","volume":"11","author":"DB Fogel","year":"2018","unstructured":"Fogel DB (2018) Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun 11:156\u2013164","journal-title":"Contemp Clin Trials Commun"},{"key":"345_CR34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA et al (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558:307\u2013312","journal-title":"Nature"},{"key":"345_CR35","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.2025029532","volume":"146","author":"MB Geyer","year":"2025","unstructured":"Geyer MB, DeWolf S, Mi X et al (2025) CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. Blood 146:3163\u20133174","journal-title":"Blood"},{"key":"345_CR36","first-page":"427","volume":"391","author":"S Gottschalk","year":"2015","unstructured":"Gottschalk S, Rooney CM (2015) Adoptive T-cell immunotherapy. Curr Top Microbiol Immunol 391:427\u2013454","journal-title":"Curr Top Microbiol Immunol"},{"key":"345_CR37","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood-2024-200932","volume":"144","author":"N Grover","year":"2024","unstructured":"Grover N, Moore D, Ivanova A et al (2024a) CD30.CAR-T cells co-expressing the CCR4 chemokine receptor in relapsed\/refractory Hodgkin lymphoma. Blood 144:919\u2013919","journal-title":"Blood"},{"key":"345_CR38","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2352-3026(24)00064-4","volume":"11","author":"NS Grover","year":"2024","unstructured":"Grover NS, Hucks G, Riches ML et al (2024b) Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30(+) lymphoma: a phase 1 study. Lancet Haematol 11:e358\u2013e367","journal-title":"Lancet Haematol"},{"key":"345_CR39","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Riviere I et al (2023) Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov 13:829\u2013843","journal-title":"Cancer Discov"},{"key":"345_CR40","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.cell.2025.12.049","volume":"189","author":"D Hanahan","year":"2026","unstructured":"Hanahan D (2026) Hallmarks of cancer-then and now, and beyond. Cell 189:2254","journal-title":"Cell"},{"key":"345_CR41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1126\/science.adv7378","volume":"391","author":"SA Hanina","year":"2026","unstructured":"Hanina SA, Park T, Lopez M et al (2026) Sensitive CAR T cells redefine targetable CD70 expression in solid tumors. Science 391:896\u2013905","journal-title":"Science"},{"key":"345_CR42","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.4049\/jimmunol.160.12.6204","volume":"160","author":"T Haque","year":"1998","unstructured":"Haque T, Amlot PL, Helling N et al (1998) Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 160:6204\u20136209","journal-title":"J Immunol"},{"key":"345_CR43","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","volume":"360","author":"T Haque","year":"2002","unstructured":"Haque T, Wilkie GM, Taylor C et al (2002) Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360:436\u2013442","journal-title":"Lancet"},{"key":"345_CR44","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","volume":"110","author":"T Haque","year":"2007","unstructured":"Haque T, Wilkie GM, Jones MM et al (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110:1123\u20131131","journal-title":"Blood"},{"key":"345_CR45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm0596-551","volume":"2","author":"HE Heslop","year":"1996","unstructured":"Heslop HE, Ng CYC, Li C et al (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551\u2013555","journal-title":"Nat Med"},{"key":"345_CR46","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop HE, Slobod KS, Pule MA et al (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925\u2013935","journal-title":"Blood"},{"key":"345_CR47","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","volume":"194","author":"MR Hines","year":"2021","unstructured":"Hines MR, Keenan C, Maron Alfaro G et al (2021) Hemophagocytic lymphohistiocytosis-like toxicity (CAR HLH) after CD19-specific CAR T-cell therapy. Br J Haematol 194:701\u2013707","journal-title":"Br J Haematol"},{"key":"345_CR48","doi-asserted-by":"crossref","unstructured":"Ho JWY, Li L, Wong KY et al (2023) Comprehensive profiling of EBV gene expression and promoter methylation reveals latency II viral infection and sporadic abortive lytic activation in peripheral T-cell lymphomas. Viruses 15","DOI":"10.3390\/v15020423"},{"key":"345_CR49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11684-016-0436-0","volume":"10","author":"L Hu","year":"2016","unstructured":"Hu L, Lin Z, Wu Y et al (2016) Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing. Front Med 10:61\u201375","journal-title":"Front Med"},{"key":"345_CR50","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y et al (2025) In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388:1311\u20131317","journal-title":"Science"},{"key":"345_CR51","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/mt.2011.179","volume":"19","author":"LE Huye","year":"2011","unstructured":"Huye LE, Nakazawa Y, Patel MP et al (2011) Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther 19:2239\u20132248","journal-title":"Mol Ther"},{"key":"345_CR52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","volume":"31","author":"V Icheva","year":"2013","unstructured":"Icheva V, Kayser S, Wolff D et al (2013) Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 31:39\u201348","journal-title":"J Clin Oncol"},{"key":"345_CR53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","volume":"26","author":"SP Iyer","year":"2025","unstructured":"Iyer SP, Sica RA, Ho PJ et al (2025) Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol 26:110\u2013122","journal-title":"Lancet Oncol"},{"key":"345_CR54","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1200\/JCO.2023.41.16_suppl.6047","volume":"41","author":"Q Jia","year":"2023","unstructured":"Jia Q, Peng L, Chen G et al (2023) TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: the first-in-human phase 1\/2 trial. J Clin Oncol 41:6047\u20136047","journal-title":"J Clin Oncol"},{"key":"345_CR55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065519","volume":"8","author":"M Jonnalagadda","year":"2013","unstructured":"Jonnalagadda M, Brown CE, Chang WC et al (2013) Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy. PLoS One 8:e65519","journal-title":"PLoS One"},{"key":"345_CR56","doi-asserted-by":"crossref","first-page":"eadl4492","DOI":"10.1126\/science.adl4492","volume":"386","author":"TG Kang","year":"2024","unstructured":"Kang TG, Lan X, Mi T et al (2024) Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy. Science 386:eadl4492","journal-title":"Science"},{"key":"345_CR57","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40291-023-00648-z","volume":"27","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023) Tabelecleucel: first approval. Mol Diagn Ther 27:425\u2013431","journal-title":"Mol Diagn Ther"},{"key":"345_CR58","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1038\/s41467-024-47057-2","volume":"15","author":"MD Keller","year":"2024","unstructured":"Keller MD, Hanley PJ, Chi YY et al (2024a) Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment. Nat Commun 15:3258","journal-title":"Nat Commun"},{"key":"345_CR59","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41467-024-47056-3","volume":"15","author":"MD Keller","year":"2024","unstructured":"Keller MD, Schattgen SA, Chandrakasan S et al (2024b) Secondary bone marrow graft loss after third-party virus-specific T cell infusion: case report of a rare complication. Nat Commun 15:2749","journal-title":"Nat Commun"},{"key":"345_CR60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcancer.2014.01.002","volume":"26","author":"SC Kenney","year":"2014","unstructured":"Kenney SC, Mertz JE (2014) Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol 26:60\u201368","journal-title":"Semin Cancer Biol"},{"key":"345_CR61","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL (2023) CAR immune cells: design principles, resistance and the next generation. Nature 614:635\u2013648","journal-title":"Nature"},{"key":"345_CR62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"key":"345_CR63","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","volume":"12","author":"AM Leen","year":"2006","unstructured":"Leen AM, Myers GD, Sili U et al (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12:1160\u20131166","journal-title":"Nat Med"},{"key":"345_CR64","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","volume":"114","author":"AM Leen","year":"2009","unstructured":"Leen AM, Christin A, Myers GD et al (2009) Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114:4283\u20134292","journal-title":"Blood"},{"key":"345_CR65","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","volume":"121","author":"AM Leen","year":"2013","unstructured":"Leen AM, Bollard CM, Mendizabal AM et al (2013) Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121:5113\u20135123","journal-title":"Blood"},{"key":"345_CR66","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","volume":"38","author":"T Lei","year":"2024","unstructured":"Lei T, Wang Y, Zhang Y et al (2024) Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia 38:2517\u20132543","journal-title":"Leukemia"},{"key":"345_CR67","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.23.02019","volume":"42","author":"FY Lin","year":"2024","unstructured":"Lin FY, Stuckert A, Tat C et al (2024) Phase I trial of GD2.CART cells augmented with constitutive Interleukin-7 receptor for treatment of high-grade pediatric CNS tumors. J Clin Oncol 42:2769\u20132779","journal-title":"J Clin Oncol"},{"key":"345_CR68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004068","volume":"10","author":"S Linnerbauer","year":"2014","unstructured":"Linnerbauer S, Behrends U, Adhikary D et al (2014) Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders. PLoS Pathog 10:e1004068","journal-title":"PLoS Pathog"},{"key":"345_CR69","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3389\/fimmu.2019.02193","volume":"10","author":"HM Long","year":"2019","unstructured":"Long HM, Meckiff BJ, Taylor GS (2019) The T-cell response to Epstein-Barr virus-new tricks from an old dog. Front Immunol 10:2193","journal-title":"Front Immunol"},{"key":"345_CR70","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","volume":"33","author":"CU Louis","year":"2010","unstructured":"Louis CU, Straathof K, Bollard CM et al (2010) Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 33:983\u2013990","journal-title":"J Immunother"},{"key":"345_CR71","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/cncr.20188","volume":"100","author":"KG Lucas","year":"2004","unstructured":"Lucas KG, Salzman D, Garcia A et al (2004) Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 100:1892\u20131901","journal-title":"Cancer"},{"key":"345_CR72","volume":"123","author":"FM Lum","year":"2026","unstructured":"Lum FM, Sattarnezhad N, Ho PP et al (2026) Multiple molecular mimics in Epstein Barr nuclear Antigen-1, and the pathogenesis of multiple sclerosis. Proc Natl Acad Sci USA 123:e2519445123","journal-title":"Proc Natl Acad Sci USA"},{"key":"345_CR73","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E et al (2019) C-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576:293\u2013300","journal-title":"Nature"},{"key":"345_CR74","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"KM Mahadeo","year":"2024","unstructured":"Mahadeo KM, Baiocchi R, Beitinjaneh A et al (2024) Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncol 25:376\u2013387","journal-title":"Lancet Oncol"},{"key":"345_CR75","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.18828","volume":"202","author":"M McKenna","year":"2023","unstructured":"McKenna M, Epperla N, Ghobadi A et al (2023) Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD. Br J Haematol 202:248\u2013255","journal-title":"Br J Haematol"},{"key":"345_CR76","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-024-13400-5","volume":"25","author":"F Meng","year":"2025","unstructured":"Meng F, Xiang M, Liu Y et al (2025) Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed\/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis. BMC Cancer 25:78","journal-title":"BMC Cancer"},{"key":"345_CR77","doi-asserted-by":"crossref","unstructured":"Morales-Sanchez A, Fuentes-Panana EM (2018) The immunomodulatory capacity of an Epstein-Barr virus abortive lytic cycle: potential contribution to viral tumorigenesis. Cancers (Basel) 10","DOI":"10.3390\/cancers10040098"},{"key":"345_CR78","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20040730","volume":"199","author":"C Munz","year":"2004","unstructured":"Munz C (2004) Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J Exp Med 199:1301\u20131304","journal-title":"J Exp Med"},{"key":"345_CR79","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","volume":"17","author":"C Munz","year":"2019","unstructured":"Munz C (2019) Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol 17:691\u2013700","journal-title":"Nat Rev Microbiol"},{"key":"345_CR80","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY et al (2022) PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 28:724\u2013734","journal-title":"Nat Med"},{"key":"345_CR81","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.1038\/s41467-024-54595-2","volume":"15","author":"MA Neller","year":"2024","unstructured":"Neller MA, Ambalathingal GR, Hamad N et al (2024) Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years. Nat Commun 15:10339","journal-title":"Nat Commun"},{"key":"345_CR82","first-page":"5745","volume":"4","author":"AS Nelson","year":"2020","unstructured":"Nelson AS, Heyenbruch D, Rubinstein JD et al (2020) Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Adv 4:5745\u20135754","journal-title":"Blood Adv"},{"key":"345_CR83","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/CJI.0000000000000014","volume":"37","author":"MC Ngo","year":"2014","unstructured":"Ngo MC, Ando J, Leen AM et al (2014) Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother 37:193\u2013203","journal-title":"J Immunother"},{"key":"345_CR84","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/bloodadvances.2023011626","volume":"8","author":"S Nikiforow","year":"2024","unstructured":"Nikiforow S, Whangbo JS, Reshef R et al (2024) Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Adv 8:3001\u20133012","journal-title":"Blood Adv"},{"key":"345_CR85","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-026-10235-x","volume":"652","author":"WA Nyberg","year":"2026","unstructured":"Nyberg WA, Bernard PL, Ngo W et al (2026) In vivo site-specific engineering to reprogram T cells. Nature 652:712","journal-title":"Nature"},{"key":"345_CR86","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","volume":"4","author":"Y Okuno","year":"2019","unstructured":"Okuno Y, Murata T, Sato Y et al (2019) Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol 4:404\u2013413","journal-title":"Nat Microbiol"},{"key":"345_CR87","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","volume":"14","author":"SK Pal","year":"2024","unstructured":"Pal SK, Tran B, Haanen J et al (2024) CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov 14:1176\u20131189","journal-title":"Cancer Discov"},{"key":"345_CR88","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","volume":"330","author":"EB Papadopoulos","year":"1994","unstructured":"Papadopoulos EB, Ladanyi M, Emanuel D et al (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185\u20131191","journal-title":"N Engl J Med"},{"key":"345_CR89","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008825","volume":"6","author":"A Papadopoulou","year":"2014","unstructured":"Papadopoulou A, Gerdemann U, Katari UL et al (2014) Activity of broad-Spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 6:242ra83","journal-title":"Sci Transl Med"},{"key":"345_CR90","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","volume":"52","author":"KS Peggs","year":"2011","unstructured":"Peggs KS, Thomson K, Samuel E et al (2011) Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 52:49\u201357","journal-title":"Clin Infect Dis"},{"key":"345_CR91","doi-asserted-by":"crossref","unstructured":"Pender MP, Csurhes PA, Smith C et al (2018) Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight 3","DOI":"10.1172\/jci.insight.124714"},{"key":"345_CR92","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-12-2143","volume":"19","author":"SK Perna","year":"2013","unstructured":"Perna SK, De AB PD et al (2013) Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 19:106\u2013117","journal-title":"Clin Cancer Res"},{"key":"345_CR93","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","volume":"29","author":"T Pfeiffer","year":"2023","unstructured":"Pfeiffer T, Tzannou I, Wu M et al (2023) Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting. Clin Cancer Res 29:324\u2013330","journal-title":"Clin Cancer Res"},{"key":"345_CR94","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJM199401133300204","volume":"330","author":"DL Porter","year":"1994","unstructured":"Porter DL, Roth MS, McGarigle C et al (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100\u2013106","journal-title":"N Engl J Med"},{"key":"345_CR95","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing B, Zebley CC, Petersen CT et al (2021) Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med 13:eabh0272","journal-title":"Sci Transl Med"},{"key":"345_CR96","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","volume":"130","author":"S Prockop","year":"2020","unstructured":"Prockop S, Doubrovina E, Suser S et al (2020) Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest 130:733\u2013747","journal-title":"J Clin Invest"},{"key":"345_CR97","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264\u20131270","journal-title":"Nat Med"},{"key":"345_CR98","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2022-160244","volume":"140","author":"DH Quach","year":"2022","unstructured":"Quach DH, Ramos CA, Lulla PD et al (2022) CD30.CAR-modified Epstein-Barr virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma. Blood 140:412\u2013414","journal-title":"Blood"},{"key":"345_CR99","volume":"32","author":"DH Quach","year":"2024","unstructured":"Quach DH, Ganesh HR, Briones YD et al (2024) Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30(+) lymphoma. Mol Ther Oncologia 32:200814","journal-title":"Mol Ther Oncologia"},{"key":"345_CR100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW et al (2020) Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 38:JCO2001342","journal-title":"J Clin Oncol"},{"key":"345_CR101","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","volume":"31","author":"K Rejeski","year":"2025","unstructured":"Rejeski K, Hill JA, Dahiya S et al (2025) Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat Med 31:2132\u20132146","journal-title":"Nat Med"},{"key":"345_CR102","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood-2014-01-553362","volume":"124","author":"I Ricciardelli","year":"2014","unstructured":"Ricciardelli I, Blundell MP, Brewin J et al (2014) Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 124:2514\u20132522","journal-title":"Blood"},{"key":"345_CR103","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41571-024-00873-3","volume":"21","author":"D Romero","year":"2024","unstructured":"Romero D (2024) Tabelecleucel is effective in EBV-positive lymphoproliferative disease. Nat Rev Clin Oncol 21:251","journal-title":"Nat Rev Clin Oncol"},{"key":"345_CR104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","volume":"345","author":"CM Rooney","year":"1995","unstructured":"Rooney CM, Smith CA, Ng C et al (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345:9\u201313","journal-title":"Lancet"},{"key":"345_CR105","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","volume":"92","author":"CM Rooney","year":"1998","unstructured":"Rooney CM, Smith CA, Ng CYC et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549\u20131555","journal-title":"Blood"},{"key":"345_CR106","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1182\/blood.V128.22.2990.2990","volume":"128","author":"RH Rouce","year":"2016","unstructured":"Rouce RH, Mehta B, Sharma S et al (2016) Rapidly-generated EBV-specific T cells (EBVST-cells) to treat type 2 latency lymphoma. Blood 128:2990\u20132990","journal-title":"Blood"},{"key":"345_CR107","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Williams JZ, Morsut L et al (2016) Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167:419\u2013432 e16","journal-title":"Cell"},{"key":"345_CR108","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/bloodadvances.2021006309","volume":"6","author":"JD Rubinstein","year":"2022","unstructured":"Rubinstein JD, Lutzko C, Leemhuis T et al (2022) Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. Blood Adv 6:2897\u20132907","journal-title":"Blood Adv"},{"key":"345_CR109","doi-asserted-by":"crossref","first-page":"119 e1","DOI":"10.1016\/j.jtct.2025.10.006","volume":"32","author":"B Salter","year":"2026","unstructured":"Salter B, Suleman A, Kridel R et al (2026) CAR-T for Management of R\/R PTLD following lung transplant: a multi-center retrospective study. Transplant Cell Ther 32:119 e1\u2013119 e6","journal-title":"Transplant Cell Ther"},{"key":"345_CR110","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/00007890-200109270-00017","volume":"72","author":"B Savoldo","year":"2001","unstructured":"Savoldo B, Goss J, Liu Z et al (2001) Generation of autologous Epstein Barr virus (EBV)-specific cytotoxic T cells (CTL) for adoptive immunotherapy in solid organ transplant recipients. Transplantation 72:1078\u20131086","journal-title":"Transplantation"},{"key":"345_CR111","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","volume":"108","author":"B Savoldo","year":"2006","unstructured":"Savoldo B, Goss JA, Hammer MM et al (2006) Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108:2942\u20132949","journal-title":"Blood"},{"key":"345_CR112","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/annonc\/mdr134","volume":"23","author":"S Secondino","year":"2012","unstructured":"Secondino S, Zecca M, Licitra L et al (2012) T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol 23:435\u2013441","journal-title":"Ann Oncol"},{"key":"345_CR113","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1158\/1078-0432.CCR-15-0124","volume":"21","author":"B Seruga","year":"2015","unstructured":"Seruga B, Ocana A, Amir E et al (2015) Failures in phase III: causes and consequences. Clin Cancer Res 21:4552\u20134560","journal-title":"Clin Cancer Res"},{"key":"345_CR114","first-page":"20160271","volume":"372","author":"C Shannon-Lowe","year":"2017","unstructured":"Shannon-Lowe C, Rickinson AB, Bell AI (2017) Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond Ser B Biol Sci 372:20160271","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"key":"345_CR115","doi-asserted-by":"crossref","first-page":"e006267","DOI":"10.1136\/jitc-2022-006267","volume":"11","author":"S Sharma","year":"2023","unstructured":"Sharma S, Woods M, Mehta NU et al (2023a) Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer 11:e006267","journal-title":"J Immunother Cancer"},{"key":"345_CR116","doi-asserted-by":"crossref","unstructured":"Sharma S, Sauer T, Omer BA et al (2023b) Constitutive Interleukin-7 cytokine signaling enhances the persistence of Epstein-Barr virus-specific T-cells. Int J Mol Sci 24","DOI":"10.3390\/ijms242115806"},{"key":"345_CR117","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2023012183","volume":"8","author":"S Sharma","year":"2024","unstructured":"Sharma S, Mehta NU, Sauer T et al (2024) Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma. Blood Adv 8:3360\u20133371","journal-title":"Blood Adv"},{"key":"345_CR118","doi-asserted-by":"crossref","unstructured":"Shechter O, Sausen DG, Gallo ES et al (2022) Epstein-Barr virus (EBV) epithelial associated malignancies: exploring pathologies and current treatments. Int J Mol Sci 23","DOI":"10.3390\/ijms232214389"},{"key":"345_CR119","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"Shum T, Omer B, Tashiro H et al (2017) Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov 7:1238\u20131247","journal-title":"Cancer Discov"},{"key":"345_CR120","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2024.103169","volume":"88","author":"JC Siebart","year":"2024","unstructured":"Siebart JC, Chan CS, Yao X et al (2024) In vivo gene delivery to immune cells. Curr Opin Biotechnol 88:103169","journal-title":"Curr Opin Biotechnol"},{"key":"345_CR121","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1016\/j.ymthe.2024.09.015","volume":"32","author":"N Singh","year":"2024","unstructured":"Singh N (2024) Approval of the first TCR-based cell therapy. Mol Ther 32:3195","journal-title":"Mol Ther"},{"key":"345_CR122","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/0008-5472.CAN-11-3399","volume":"72","author":"C Smith","year":"2012","unstructured":"Smith C, Tsang J, Beagley L et al (2012) Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 72:1116\u20131125","journal-title":"Cancer Res"},{"key":"345_CR123","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/mt.2010.223","volume":"19","author":"XT Song","year":"2010","unstructured":"Song XT, Turnis M, Zhou X et al (2010) A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther 19:211\u2013217","journal-title":"Mol Ther"},{"key":"345_CR124","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A et al (2025) Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637:940\u2013946","journal-title":"Nature"},{"key":"345_CR125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14653240310001497","volume":"5","author":"KC Straathof","year":"2003","unstructured":"Straathof KC, Spencer DM, Sutton RE et al (2003) Suicide genes as safety switches in T lymphocytes. Cytotherapy 5:227\u2013230","journal-title":"Cytotherapy"},{"key":"345_CR126","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Bollard CM, Popat U et al (2005) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105:1898\u20131904","journal-title":"Blood"},{"key":"345_CR127","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/mt.sj.6300134","volume":"15","author":"MM Suhoski","year":"2007","unstructured":"Suhoski MM, Golovina TN, Aqui NA et al (2007) Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 15:981\u2013988","journal-title":"Mol Ther"},{"key":"345_CR128","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-17-1298","volume":"8","author":"S Sukumaran","year":"2018","unstructured":"Sukumaran S, Watanabe N, Bajgain P et al (2018) Enhancing the potency and specificity of engineered T cells for cancer treatment. Cancer Discov 8:972\u2013987","journal-title":"Cancer Discov"},{"key":"345_CR129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-9378-7-21","volume":"7","author":"W Tang","year":"2012","unstructured":"Tang W, Morgan DR, Meyers MO et al (2012) Epstein-Barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile. Infect Agent Cancer 7:21","journal-title":"Infect Agent Cancer"},{"key":"345_CR130","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","volume":"33","author":"GS Taylor","year":"2015","unstructured":"Taylor GS, Long HM, Brooks JM et al (2015) The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol 33:787\u2013821","journal-title":"Annu Rev Immunol"},{"key":"345_CR131","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.virol.2014.10.030","volume":"474","author":"RJ Tierney","year":"2015","unstructured":"Tierney RJ, Shannon-Lowe CD, Fitzsimmons L et al (2015) Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. Virology 474:117\u2013130","journal-title":"Virology"},{"key":"345_CR132","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.annonc.2024.08.2344","volume":"35","author":"HC Toh","year":"2024","unstructured":"Toh HC, Yang MH, Wang HM et al (2024) Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol 35:1181\u20131190","journal-title":"Ann Oncol"},{"key":"345_CR133","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","volume":"35","author":"I Tzannou","year":"2017","unstructured":"Tzannou I, Papadopoulou A, Naik S et al (2017) Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 35:3547\u20133557","journal-title":"J Clin Oncol"},{"key":"345_CR134","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tong C, Dai H et al (2021) Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun 12:409","journal-title":"Nat Commun"},{"key":"345_CR135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.10.004","volume":"97","author":"X Wang","year":"2023","unstructured":"Wang X, Eichhorn PJA, Thiery JP (2023) TGF-beta, EMT, and resistance to anti-cancer treatment. Semin Cancer Biol 97:1\u201311","journal-title":"Semin Cancer Biol"},{"key":"345_CR136","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1189\/jlb.3MR0315-136R","volume":"99","author":"F Wein","year":"2016","unstructured":"Wein F, Kuppers R (2016) The role of T cells in the microenvironment of Hodgkin lymphoma. J Leukoc Biol 99:45\u201350","journal-title":"J Leukoc Biol"},{"key":"345_CR137","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke M, Araujo DM, Chatterjee M et al (2025) Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: a phase 1 trial. Nat Med 31:2365\u20132374","journal-title":"Nat Med"},{"key":"345_CR138","doi-asserted-by":"crossref","unstructured":"Wilson JB, Manet E, Gruffat H et al (2018) EBNA1: oncogenic activity, immune evasion and biochemical functions provide targets for novel therapeutic strategies against Epstein-Barr virus-associated cancers. Cancers (Basel) 10","DOI":"10.3390\/cancers10040109"},{"key":"345_CR139","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/bloodadvances.2023010832","volume":"8","author":"B Wistinghausen","year":"2024","unstructured":"Wistinghausen B, Toner K, Barkauskas DA et al (2024) Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a children's oncology group study. Blood Adv 8:1116\u20131127","journal-title":"Blood Adv"},{"key":"345_CR140","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","volume":"1","author":"B Withers","year":"2017","unstructured":"Withers B, Blyth E, Clancy LE et al (2017) Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv 1:2193\u20132205","journal-title":"Blood Adv"},{"key":"345_CR141","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1182\/bloodadvances.2025016141","volume":"9","author":"K Wudhikarn","year":"2025","unstructured":"Wudhikarn K, Herr MM, Chen M et al (2025) Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR. Blood Adv 9:5460\u20135472","journal-title":"Blood Adv"},{"key":"345_CR142","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/jpids\/piad097","volume":"13","author":"M Yamada","year":"2024","unstructured":"Yamada M, L'Huillier AG, Green M (2024) A focused review of Epstein-Barr virus infections and PTLD in pediatric transplant recipients: guidance from the IPTA and ECIL guidelines. J Pediatric Infect Dis Soc 13:S31\u2013S38","journal-title":"J Pediatric Infect Dis Soc"},{"key":"345_CR143","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/hed.25131","volume":"40","author":"F Yu","year":"2018","unstructured":"Yu F, Lu Y, Petersson F et al (2018) Presence of lytic Epstein-Barr virus infection in nasopharyngeal carcinoma. Head Neck 40:1515\u20131523","journal-title":"Head Neck"},{"key":"345_CR144","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","volume":"25","author":"CC Zebley","year":"2024","unstructured":"Zebley CC, Zehn D, Gottschalk S et al (2024) T cell dysfunction and therapeutic intervention in cancer. Nat Immunol 25:1344\u20131354","journal-title":"Nat Immunol"},{"key":"345_CR145","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/gt.2012.75","volume":"20","author":"L Zhang","year":"2013","unstructured":"Zhang L, Yu Z, Muranski P et al (2013) Inhibition of TGF-beta signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther 20:575\u2013580","journal-title":"Gene Ther"},{"key":"345_CR146","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang L, Morgan RA, Beane JD et al (2015) Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 21:2278\u20132288","journal-title":"Clin Cancer Res"},{"key":"345_CR147","doi-asserted-by":"crossref","unstructured":"Zheng X, Huang Y, Li K et al (2022) Immunosuppressive tumor microenvironment and immunotherapy of Epstein-Barr virus-associated malignancies. Viruses 14","DOI":"10.3390\/v14051017"}],"container-title":["Current Topics in Microbiology and Immunology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2026_345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T06:44:15Z","timestamp":1779864255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2026_345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":147,"URL":"https:\/\/doi.org\/10.1007\/82_2026_345","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"28 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}